screening process time, from 7.8 hours (range 4 to 11.6) in the control to 3.5 hours (range 1.8 to 5.2) in the active period, a statistically significant difference of 4.3 hours (95% CI 0.2 to 8.5, $p=0.039$). The transcribing error rate during the active period was 4%, lower than the 27% in the control period ($\chi^2(1)=36.46$, $p<0.001$).

Conclusion and relevance Involving OWPs in transcribing supportive medication reduced the IPChx delivery time and the occurrence of transcribing errors. Nonetheless, inconsistencies between current practice and hospital targets raised important issues that may imply that a further evaluation of the whole IPChx process is required. Consequently, further research is required to establish if additional interventions are required to improve waiting times for oncology patients.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Conflict of interest Corporate sponsored research or other substantive relationships:

This project was completed as part of the MSc Advanced Clinical Pharmacy Practice programme at Queen's University Belfast. This was funded with the Pharmacy Fund Award granted by the Southampton Pharmacy Research Centre at University Hospital Southampton NHS Foundation Trust.

4CPS-179 THE WIDE REVIEW OF POLYPHARMACY IN THE FRAIL OLDER PERSON

¹C Kinahan*, ²H Heery. ¹Portiuncula University Hospital, Pharmacy Department, Co Galway, Ireland; ²Portiuncula University Hospital, Pharmacy Department, Ballinasloe, Ireland

10.1136/ejhp-pharm-2020-eahpconf.280

Background and importance The WIDE (Wholistic Integrated Deprescribing Evaluation) review is an innovative model of patient-led, pharmacist facilitated medication review. It involves establishing patients' priorities and experiences of their medicines, collaborating with primary care providers and evaluating if medicines should be deprescribed because their potential harms outweigh their potential benefits. Frailty is synonymous with vulnerability, including to medication harms. To assess the potential for harm, the WIDE review model incorporates the STOPP/START criteria and the medication appropriateness index (MAI) tools, the use of which have demonstrated improvements in patient outcomes. However, the impact of a patient-led deprescribing model has not yet been studied in this setting.

Aim and objectives To examine the impact and cost effectiveness of WIDE reviews.

Material and methods This quantitative prospective cohort study was conducted over 8 weeks.

Inclusion criteria inpatients aged >65 years and prescribed >5 regular medications who screened positive for frailty (PRISMA 7 score >3). Critically ill patients were excluded. Eligible patients were randomly allocated to the intervention or control group.

Regular medications were enumerated and screened using the STOPP/START criteria on admission and discharge. The intervention group received a WIDE review and their MAI score was calculated on admission and discharge. In conjunction with the patients and their consultants, deprescribing plans were devised and communicated to their GPs and community pharmacists.

Results A total of 20 intervention and 20 control group patients were enrolled. Patient characteristics (age, sex and

length of stay) were similar for both groups. A total of 65% of STOPP and 62% of START criteria were addressed in the intervention group versus 12% and 5%, respectively, in the control group. In the intervention group, 83 medications were stopped, 23 doses were reduced and the total MAI score was reduced by 64%. Cost savings to the annual drug budget alone represented a 9:1 return on investment of hospital pharmacist time. Most discontinuations and dose reductions were sustained (98%) and 92% of future recommendations were enacted on 6 months of follow-up.

Conclusion and relevance Pharmacists performing patient-led WIDE reviews significantly improved medication appropriateness and realised compelling cost savings. A large scale, multi-site study is warranted to demonstrate the reproducibility of these results.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-180 FROM EVIDENCE BASED MEDICINE TO PRACTICE: GUM CHEWING FOR POSTOPERATIVE RECOVERY OF GASTROINTESTINAL FUNCTION AFTER COLORECTAL SURGERY WITH INTERPROFESSIONAL TEAMWORK

¹YN Lin*, ²CL Chuan, ³CS Tsai. ¹Tainan Municipal Hospital managed by Show Chwan Medical Care Corporation, Pharmacy, Tainan, Taiwan ROC; ²Tainan Municipal Hospital managed by Show Chwan Medical Care Corporation, Nutrition and Dietetics, Tainan, Taiwan ROC; ³Tainan Municipal Hospital managed by Show Chwan Medical Care Corporation, Internal Medicine, Tainan, Taiwan ROC

10.1136/ejhp-pharm-2020-eahpconf.281

Background and importance Flatus is an important indicator of postoperative recovery of gastrointestinal function. Gum chewing is a cheap and simple intervention that mimics food intake to stimulate the vagus nerve and bowel movements.

Aim and objectives To confirm the efficacy of gum chewing through an evidence approach and to implement this approach through interprofessional teamwork.

Material and methods Evidence approach: setting the patient, intervention, comparison and outcome (PICO) to form a therapy question. In the Pubmed, Cochrane and Embase databases, using MeSH terms and Boolean logic combinations (chewing gum AND (colorectal surgery OR colostomy) AND postoperative ileus) for the literature search. Filters activated were randomised controlled trial (RCT), published from 2000 to 2018, in humans. Eleven RCTs were selected for review and showed a trend in improvement in the time to first flatus, starting feeding and discharge.

Implementation we formed an interprofessional team including physicians, nurses, dieticians and pharmacists. The study involved 39 patients who underwent colorectal surgery between March and August 2018. In the gum chewing group, 19 patients took gum three times a day on the first day after surgery until the first flatus. Twenty patients who disagreed with gum chewing were in the control group. Evaluation of the findings was done with analysis of covariance (ANCOVA).

Results Compared with the control group, the time to first flatus and the start of feeding were shorter in the gum chewing group (66.97 ± 24.78 vs 54.82 ± 19.74 hours and 91.53 ± 51.41 vs 74.77 ± 21.54 hours, respectively). However, the difference was not significant ($p=0.166$, 0.283). The time to discharge was significantly shorter in the gum chewing group (12.55 ± 5.96 vs 9.16 ± 1.71 days, $p=0.047$). Other influencing

factors for the time to first flatus, start of feeding and discharge were analysed (eg, taking promotility agents, such as metoclopramide), but no significant differences were found between the two groups ($p=0.375$, 0.162 , 0.960).

Conclusion and relevance Could evidence based medicine lead to an equally satisfying practice? The implementation of the interprofessional team was essential (eg, the core physician team had not participated at the beginning and thus missed many possible cases).

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-181 BUDGETARY IMPACT OF BIOSIMILAR PRESCRIPTION IN THE TREATMENT OF RHEUMATIC DISEASES

A Linares*, C Fernandez Cuerva, R Asensi Diez, I Muñoz Castillo. *Hru Carlos Haya, Pharmacy, Malaga, Spain*

10.1136/ejhp-2020-eahpconf.282

Background and importance Biological medicines for the treatment of rheumatological diseases requires a large budget in our hospital as the number of patients and drugs involved increase each year, making it essential to implement containment policies. Our pharmacy service has promoted biosimilar prescriptions in order to improve the efficiency of our health system.

Aim and objectives To evaluate the economic impact on the cost per patient of the use of biological products in the area of rheumatology since the implementation of biosimilar drug prescriptions.

Material and methods A retrospective analysis of pharmaceutical expenditure for biological drugs prescribed for rheumatological pathologies was conducted from January 2016 to December 2018. Data collected were budget, biological therapies and number of patients treated. Data were collected from electronic prescribing and economic software (Athos).

Results During the study period, 1704 patients received biological drugs prescribed by the rheumatology service, which supposed an expenditure of 13 904 349.46€. Therapies prescribed were: etanercept (36.03%), adalimumab (18.99%), golimumab (14.43%), tocilizumab (12%), infliximab (9.31%) and certolizumab (6.24%); abatacept, ustekinumab, rituximab and anakinra were prescribed in <1% of patients.

In 2017, biosimilar prescriptions in rheumatology were promoted in such a way that the start of treatment (naïve patients) had to be performed with a biosimilar medicine. This strategy began with infliximab and etanercept, and supposed a growth in the percentage of prescribed biosimilars. In 2018 versus 2017, the percentages of infliximab biosimilar were 35% versus 18%. In 2018 versus 2017, the percentages of etanercept biosimilar were 55% versus 21%. By the end of 2018, adalimumab biosimilar started to be prescribed, reaching 2% of all prescriptions of adalimumab.

Abstract 4CPS-181 Table 1

	2016	2017	2018
Budget (€)	4 888 129.59	4 526 851.82	4 489 368.05
Patients	671	704	819
Cost/patient/month (€)	607.07	535.85	456.79

Table 1 shows the evolution for biologics expenditure in rheumatology.

Conclusion and relevance Biosimilar prescription strategies in rheumatology have led to an increase in the number of patients treated with a cost/patient/month reduction of approximately 25%. More patients have been treated each year with the same annual budget which reinforces the importance of the biosimilar prescription.

REFERENCES AND/OR ACKNOWLEDGEMENTS

- Grupo de trabajo de la GUIPCAR. *Guía de Práctica Clínica para el Manejo de Pacientes con Artritis Reumatoide*. Madrid. Sociedad Española de Reumatología. 2019. (Accessed October 2019). Available at: <https://www.ser.es/wp-content/uploads/2019/04/Guia-de-Practica-Clinica-para-el-Manejo-de-Pacientes-con-Artritis-Reumatoide.pdf>

No conflict of interest.

4CPS-182 PRELIMINARY DESIGN OF HOSPITAL TELEPHARMACY

- ¹K Nikou, ²V Papandreou, ³AA Volakaki, ⁴SA Koufopoulou, ⁵C Allagianni, ⁵D Makridaki*. ¹General Hospital of Chest Diseases 'Sotiria', Pharmacy, Athens, Greece; ²Evangelismos Hospital, Pharmacy, Athens, Greece; ³Panarkadiko Hospital, Pharmacy, Tripoli, Greece; ⁴Naxos Hospital, Pharmacy, Naxos, Greece; ⁵General Hospital of Attica 'Sismanoglio-Amalia Fleming', Pharmacy, Athens, Greece

10.1136/ejhp-2020-eahpconf.283

Background and importance Due to the economic crisis, many hospitals in our country, especially those located in remote areas and on the islands, have limited hospital pharmacist coverage (one hospital pharmacist per hospital). Telepharmacy addresses the shortages of pharmacists in rural areas.

Aim and objectives To ensure that inexperienced hospital pharmacists, working in small rural hospitals, are sufficiently supported and educated by their experienced colleagues.

Material and methods In this preliminary study, two inexperienced hospital pharmacists interacted on a daily basis with three experienced colleagues employed in tertiary hospitals, analysing administrative duties and sharing best practice approaches for a period of 1 year to establish a common working framework. The methods of communication included calls, teleconference/video calls and emails. The experienced hospital pharmacists were available for immediate contact.

Results Over 1 year, 672 communications via telephone or email (regarding 168 problems, average 4 communications per problem) were recorded for both rural hospitals. Twice monthly, scheduled teleconference/video calls were conducted to stabilise the procedures and check on the follow-up of the interventions. In total, 21 video calls were conducted.

Problems were categorised into four main fields: (1) pharmacy management (38%) (eg, daily practice, shortages, procurement, IT problems); (2) administrative issues (28%) (eg, SOPs, personnel duties, out of pharmacy collaborations); (3) scientific issues (23%) (eg, pharmacovigilance, antibiotic stewardship, risk assessment and safety problems); and (4) patients' and healthcare professionals (HCPs)' education and consultancy (11%). From the 168 problems discussed, 106 (63%) were successfully resolved, 43 (26%) are still ongoing but positively progressing and 19 (11%) remained unresolved and difficult to overcome, as they may demand consent of other HCPs, hospital manager and/or the Ministry of Health. The study interviewees completed questionnaires every 3 months, assessing the following indexes: response time (reduced), the percentage of resolved problems (increased, mostly for those